IGF1R and metabolic dysfunction-associated steatohepatitis: They offer protective effects on NASH progression by inhibiting the expression of profibrotic genes that miR-223 targets, including C-X-C motif chemokine (Cxcl10), NOD-, LRR—and pyrin domain-containing protein 3 (Nlrp3), transcriptional activator with PDZ-binding (Taz), and insulin-like Growth Factor 1 Receptor (Igf1r) in the liver.